KRAS and cancer: In addition, to increase the antitumor effect because the efficacy of TAK-981 monotherapy was modest in vivo, as described above, we next focused on the co-inhibition of SUMOylation and MEK because the MAPK pathway plays critical roles in KRAS-mutant cancer [23].